Peptide LexiconAll compounds

PE-22-28: The Seven-Amino-Acid Spadin Fragment Sold as a Nootropic — What It Is and What One Mouse Paper Shows

PE-22-28 is a seven-amino-acid fragment of spadin, a peptide cut from the sortilin propeptide. French researchers designed it in 2017 to block the TREK-1 potassium channel longer than spadin does, and reported antidepressant-like effects in mice. One indexed paper describes it; no human study is published or registered.

Not approved anywhereNo human study published or registeredOne indexed paper

Caroline S · Published 2026-11-12

Length

7 amino acids — named by its position, residues 22 to 28 of the sortilin propeptide (PE); spadin is PE 12-28 (Djillani et al. 2017, PMID 28955242)

Sequence

Not printed in the 2017 paper, which names the peptide by position only. PubChem's spadin record (CID 91826106) has the formula of the 18-residue chain YAPLPRWSGPIGVSWGLR (our check); its last seven residues are GVSWGLR, the sequence sellers commonly list — our reading, not stated in the primary source

Origin

Synthetic; designed at the Institut de Pharmacologie Moléculaire et Cellulaire (CNRS, Université Côte d'Azur, Valbonne) from the breakdown products of spadin in mouse blood (PMID 28955242)

Last reviewed

2026-11-12

What is it good for?

Sellers present it as a fast-acting nootropic and mood peptide. The research behind that is one 2017 paper: in cells, it blocked the TREK-1 potassium channel more tightly than spadin; in mice, it shortened immobility in a forced-swim test, reduced latency in a novelty-feeding test and increased markers of new neurons and synapses. No study in people exists.

Illustration: A deep green glass flask with a stopper on a white surface, with soft shadows.
Illustration

What it is

PE-22-28 is a seven-amino-acid peptide cut down from spadin, a peptide its discoverers called "the first natural antidepressant peptide identified." The story has three steps:

  1. When the receptor sortilin (also called NTSR3) matures, it releases a propeptide — the "PE" in the name.
  2. In 2010, a CNRS team in Valbonne described spadin, the piece of that propeptide from position 12 to 28, as a blocker of the TREK-1 potassium channel with antidepressant-like effects in mice (Mazella et al., PLoS Biology, PMID 20405001).
  3. In 2017 that team watched spadin break down in mouse blood, tested the fragments, and found that the shortest one still working was residues 22 to 28 — PE-22-28 (Djillani et al., Frontiers in Pharmacology, PMID 28955242).

The 2017 paper names the peptide by position only; it does not print its letters. PubChem's spadin record (CID 91826106) has the formula C96H142N26O22, which matches the 18-residue chain YAPLPRWSGPIGVSWGLR by our own residue-mass check. Its last seven residues are GVSWGLR, the sequence sellers usually list — our reading, labelled as such.

What the one paper shows

Test Result (PMID 28955242)
TREK-1 block, human channel in HEK cells IC50 0.12 nM vs 40–60 nM for spadin; 55.5 ± 4.6% inhibition (13 cells)
Shorter fragments PE 22-27 and PE 22-25 did not significantly inhibit TREK-1
Forced-swim test, mice Immobility reduced; in a corticosterone model, 98.1 s at 3.0 µg/kg vs 117.4 s for spadin at 100 µg/kg (10 mice per group)
Novelty-suppressed feeding, 4 days Latency to eat reduced
Duration of effect Up to 23 hours vs 7 hours for spadin
Brain-cell markers Neurogenesis after 4 days in mice; more PSD-95 in cultured mouse cortical neurons

The paper also tested modified versions — biotinylated, methylated, a glycine-to-alanine swap — and reported that several kept their activity while others, such as the palmitoyl and stearic-acid versions, lost most of it.

What is not established

  • Any effect in people. No human study is published, and ClinicalTrials.gov lists none for PE-22-28 or spadin (2026-11-12).
  • Memory, focus or "nootropic" effects. The paper measured depression-like behaviour, not cognition.
  • Safety. The paper reports no toxicology, and none is indexed elsewhere.
  • Replication. Every finding comes from the group that designed the peptide; PubMed indexes one paper that names PE-22-28.
  • How it reaches the brain in people. The mice received it by injection into the abdomen.

Where it stands

  • Approved: nowhere; the US drug databases return nothing for it.
  • Sold as: a research peptide marketed for mood and focus; this library does not review products.
  • Research record: one PubMed paper (2017); spadin 83 records; no registered trial (2026-11-12).

The peptides most often sold beside it for focus have longer records: Selank and Semax, both registered medicines in Russia, and noopept, a modified dipeptide designed in Moscow. Dihexa shares PE-22-28's position as a compound known mostly from its developers' animal work. How the library judges that kind of evidence across the class is set out in the focus and mood overview.

What the research shows

Blocks the TREK-1 potassium channel

Patch-clamp on human TREK-1 expressed in HEK cells: IC50 0.12 nM vs 40–60 nM for spadin; 55.5 ± 4.6% inhibition (n = 13 cells) (PMID 28955242)

Has antidepressant effects

Mouse behaviour tests only — forced swim, novelty-suppressed feeding, and a corticosterone model (PMID 28955242)

Improves memory or focus

No indexed study tests memory, attention or cognition (PubMed, 2026-11-12)

Promotes new neurons

Neurogenesis after 4 days in mice and a rise in the synapse marker PSD-95 in cultured mouse cortical neurons (PMID 28955242)

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

Approved as a medicine

Nowhere; Drugs@FDA and openFDA return nothing for it (2026-11-12).

Published record

PubMed: one record names PE 22-28 in its title or abstract (PMID 28955242, 2017); the parent peptide spadin has 83 records. ClinicalTrials.gov: no study of PE-22-28 or of spadin (2026-11-12).

Evidence concentration

Every finding comes from the one research group that designed the peptide.

Frequently asked questions

What is PE-22-28?

A seven-amino-acid synthetic peptide, a shortened form of spadin. Its name gives its position: residues 22 to 28 of the propeptide released by the sortilin receptor. French researchers designed it in 2017 to last longer in the body than spadin.

What is PE-22-28 said to be good for?

Sellers present it for mood, focus and memory. The only research is one 2017 paper reporting antidepressant-like behaviour in mice and TREK-1 channel blocking in cells. No study has tested memory or focus, and none has been done in people.

How does PE-22-28 work?

In the 2017 paper it blocks TREK-1, a potassium channel in nerve cells. Mice lacking the TREK-1 gene behave as if resistant to depression, which is why blocking the channel was studied as an antidepressant idea.

Has PE-22-28 been tested in humans?

No. PubMed has one paper on it, in cells and mice, and ClinicalTrials.gov lists no study of PE-22-28 or of its parent peptide spadin (read 2026-11-12).

What is the difference between PE-22-28 and spadin?

Spadin is the longer parent peptide, PE 12-28. In the 2017 paper PE-22-28 bound the TREK-1 channel at a far lower concentration (IC50 0.12 nM vs 40–60 nM) and its effect in mice lasted up to 23 hours instead of 7. Both remain animal-research compounds.

What is PE-22-28's sequence?

The 2017 paper names it by position and does not print the letters. Counting the last seven residues of the spadin chain in PubChem gives GVSWGLR, the sequence sellers usually list; that is our reading, not a figure from the primary source.